Condition

Relapsed Refractory Multiple Myeloma (RRMM) clinical trials and research

• 7Clinical trials
• 19Countries

Newest Relapsed Refractory Multiple Myeloma (RRMM) clinical trials

All recruiting trials (7)

• REGN17372 plus linvoseltamab tolerability for adults with relapsed/refractory multiple myeloma

  This trial tests whether giving REGN17372 together with linvoseltamab is safe and what dose works for adults whose multiple myeloma has come back or stopped responding.

  Recruiting at 9 sites Phase 1/2 Regeneron Pharmaceuticals · Liverpool, New South Wales and 8 other locations · NCT07455851

• Low-dose radiation to boost elranatamab for relapsed/refractory multiple myeloma with extramedullary or paramedullary disease

  We will test whether low-dose radiation given before elranatamab helps people with relapsed or refractory multiple myeloma that has grown outside the bone or into surrounding tissue respond better to treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07382739

• Mezigdomide plus talquetamab for relapsed and refractory multiple myeloma

  This phase 1 test tries combining mezigdomide with talquetamab and dexamethasone in adults with relapsed and refractory multiple myeloma who have had at least three prior therapies to find a safe dose and see if it helps.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07032714

• Letermovir to prevent CMV in relapsed/refractory multiple myeloma patients on elranatamab

  This trial tests whether the antiviral letermovir can prevent clinically significant CMV infections in adult CMV‑seropositive patients with relapsed or refractory multiple myeloma who are receiving elranatamab.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT06920251

• Elranatamab plus under-the-skin isatuximab for relapsed/refractory multiple myeloma

  This trial will test whether combining elranatamab with subcutaneous isatuximab helps people with relapsed or refractory multiple myeloma who have had at least two prior therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06832865

• Combination of mezigdomide and elranatamab for treating relapsed multiple myeloma

  This study is testing a new combination treatment of mezigdomide and elranatamab for people with relapsed multiple myeloma to see how well it works and how safe it is.

  Recruiting at 6 sites Phase 1/2 Seoul National University Hospital · Singapore and 6 other locations · NCT06645678

• Comparing linvoseltamab to a combination of three other cancer drugs for relapsed/refractory multiple myeloma

  This study is testing if a new drug called linvoseltamab works better than a standard combination of three other cancer drugs for adults with relapsed or refractory multiple myeloma.

  Recruiting at 19 sites Phase 3 Regeneron Pharmaceuticals · Los Angeles, California and 158 other locations · NCT05730036

Related topics

Quick answers

How many Relapsed Refractory Multiple Myeloma (RRMM) clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 19 countries. The most sites are in United States (4 trials), South Korea (3 trials), Singapore (2 trials), Australia (2 trials), Greece (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1/2: 2, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →